KRAS Biomarkers
FDA Approves Amgen's Lumakras for NSCLC Alongside Companion Tests From Guardant Health, Qiagen
The approval makes Lumakras the first inhibitor of KRAS, once considered "undruggable," to reach the market for KRAS-mutated NSCLC.
Qiagen, Mirati Therapeutics Partner to Develop KRAS Companion Test for NSCLC Drug
The tissue-based test will identify cancer patients who may benefit from adagrasib, Mirati's investigational oral small molecule inhibitor of KRAS G12C.
Amgen, NeoGenomics Partner to Expand Biomarker Testing Access in NSCLC
As part of its Biomarker Assist program, Amgen will cover the cost of NeoGenomics' KRAS tests for advanced or metastatic NSCLC patients regardless of their insurance status.
Strata, Mirati Therapeutics Partner on Tumor-Agnostic Clinical Trial of Novel KRAS G12C Inhibitor
Strata will use its StrataNGS profiling test to identify patients with advanced solid tumors harboring KRAS G12C mutations for enrollment into Mirati's KRYSTAL-1 trial.
Amid COVID-19, Lower Cancer Diagnosis Rates Mean Fewer Patients Getting Molecular Tests, Treatment
Premium
Data amassed by analytics firm Diaceutics suggests fewer patients are coming into healthcare facilities and missing the chance for diagnosis, molecular testing, and treatment.